BRIEF published on 12/23/2024 at 21:09, 1 year 1 month ago Succès de l'offre publique de TME Pharma N.V. Actionnaires Augmentation De Capital Cancer NOX-A12 Stratégies Financières
BRIEF published on 12/23/2024 at 21:09, 1 year 1 month ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
PRESS RELEASE published on 12/23/2024 at 21:04, 1 year 1 month ago Informations privilégiées / Autres communiqués TME Pharma réussit son offre publique de 2,6 millions d'euros, renforçant sa position financière jusqu'en juin 2025. Les actionnaires soutiennent la levée de fonds pour NOX-A12 et NOX-E36 Augmentation De Capital Offre Publique TME Pharma NOX-A12 NOX-E36
BRIEF published on 12/04/2024 at 19:55, 1 year 2 months ago TME Pharma annonce une mise à jour stratégique et un plan de financement de 2,6 millions d'euros Stratégie D'entreprise Offre Publique Plan De Financement Développement Du NOX-A12 Priorité Aux Actionnaires
BRIEF published on 12/04/2024 at 19:55, 1 year 2 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 2 months ago Informations privilégiées / Autres communiqués TME Pharma annonce une nouvelle stratégie et un financement garanti de 2,6 millions d'euros pour ses projets NOX-A12 et NOX-E36 jusqu'en juin 2025 Financement Offre Publique TME Pharma NOX-A12 NOX-E36
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 2 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 2 months ago TME Pharma présente ses résultats sur NOX-A12 dans le glioblastome Thérapie Contre Le Cancer Glioblastome NOX-A12 Inhibition Du Point De Contrôle Immunitaire Microenvironnement Tumoral
BRIEF published on 11/23/2024 at 10:59, 1 year 2 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
PRESS RELEASE published on 11/23/2024 at 10:54, 1 year 2 months ago Informations privilégiées / Autres communiqués TME Pharma annonce la présentation d'un poster par le National Cancer Institute américain sur l'inhibition de CXCL12 par NOX-A12 dans le glioblastome à la réunion annuelle du SNO 2024 Glioblastome TME Pharma NOX-A12 National Cancer Institute Inhibition
Published on 02/20/2026 at 18:30, 1 hour 45 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 4 hours 30 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 5 hours 45 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 6 hours 7 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 6 hours 15 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 18:36, 1 hour 38 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 1 hour 44 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 2 hours 15 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 2 hours 15 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 18:00, 2 hours 15 minutes ago TERACT - Résiliation du contrat de liquidité
